Cargando…
A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?
Patients with unresectable biliary tract carcinomas (BTCs) have a poor prognosis with a median overall survival of fewer than 12 months following systemic chemotherapy. In recent years, the identification of distinct molecular alterations with corresponding targeted therapies is modifying this thera...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Open Exploration
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9400771/ https://www.ncbi.nlm.nih.gov/pubmed/36045702 http://dx.doi.org/10.37349/etat.2021.00056 |